Rafael Fonseca, Chief Innovation Officer and Professor of Medicine at Mayo Clinic, shared Haematologica’s post on X, adding:
“Sometimes we have no options.
But if at all possible, as in this case, patients that are going to CART should be treated at the point where they have minimal tumor burden.
‘The ideal CART patient doesn’t need bridging therapy.'”
Haematologica shared a post on X:
“Fatal hyperinflammatory syndrome after CAR T-cell therapy: the case of a man with extensive non-clonal CAR T-cell expansion leading to a fatal hyperinflammatory syndrome.”
Title: Extensive non-clonal CAR T-cell expansion causing fatal hyperinflammatory syndrome with immune effector cell-associated hemophagocytic lymphohistiocytosis, cytokine release syndrome, and neurotoxicity syndrome
Authors: Andreas Riedel, Anna M. P. Stanger, Lucca M. Kimmich, Stefan Hug, Adrian E. Fehn, Jan C. Schroeder, Britta Besemer, Nicolas Casadei, Germ
Read the Full Article on Haematologica
More posts featuring Rafael Fonseca.
